药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02268 药明合联

收市竞价 06-17 16:03:31

16.640

+0.280

+1.71%

最高16.960	最低16.160	成交量205.30万
今开16.880	昨收16.360	日振幅4.89%
总市值199.36亿	流通市值199.36亿	总股本11.98亿
成交额3,422万	换手率0.17%	流通股本11.98亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"药明合联","latestPrice":16.64,"timestamp":1718611260841,"preClose":16.36,"halted":0,"volume":2053000,"delay":0,"floatShares":1198104069,"shares":1198104069,"eps":0.29772744,"marketStatus":"收市竞价","marketStatusCode":4,"change":0.28,"latestTime":"06-17 16:03:31","open":16.88,"high":16.96,"low":16.16,"amount":34221450,"amplitude":0.0489,"askPrice":16.64,"askSize":142000,"bidPrice":16.64,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":0.27929099727426804,"exchange":"SEHK","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1718611800000},"adr":0,"listingDate":1700150400000,"adjPreClose":16.36,"openAndCloseTimeList":[[1718587800000,1718596800000],[1718600400000,1718611200000]],"volumeRatio":0.515142,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268/tweets","defaultTab":"tweets","newsList":[{"id":"2442555393","title":"智通港股解盘 | 生物安全法案暂停CXO迎反弹 关注晚间两重磅消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2442555393","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442555393?lang=zh_cn&edition=full","pubTime":"2024-06-12 20:14","pubTimestamp":1718194458,"startTime":"0","endTime":"0","summary":"关于加沙停火一事出现变故，哈马斯积极回应加沙停火方案，布林肯称令人鼓舞，但媒体引述以色列官员报道，哈马斯修改了所有基本内容，变相拒绝了停火建议。知情人士称，欧盟将于周三通知汽车制造商，从下月起对进口自中国的电动汽车暂时征收最高达25%的额外关税。目前是临时关税，根据欧盟法规，接下来是各成员国、制造商的协商阶段，中欧之间也将开始一系列谈判，确定细则，直到11月初则正式生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1610","SG9999001051.SGD","BK1543","HSTECH","LU0173614495.USD","LU0979878070.USD","BK1603","LU0823426308.USD","BK1576","LU2039709279.SGD","SGXZ90724238.SGD","CXO","LU0417516738.SGD","LU0823426480.USD","LU0348735423.USD","LU0456827905.SGD","LU0702159699.USD","SG9999002463.SGD","LU0516423091.SGD","SG9999002562.SGD","07226","LU0043850808.USD","LU0541502299.USD","LU1794554557.SGD","LU0359201612.USD","LU1880383366.USD","SG9999014674.SGD","LU0359202008.SGD","LU0052750758.USD","01610","02268","LU0320764599.SGD","LU0181495838.USD","LU0417516902.SGD","BK1171","BK1521","00288","BK1589","BK1549","LU0541501648.USD","02269","HSCEI","00564","LU0856984785.SGD","LU0327786744.USD","BK1141","YANG","SG9999001069.SGD","LU0051755006.USD","LU0516423174.USD"],"gpt_icon":0},{"id":"2442929533","title":"《生物安全法案》危机暂时解除，CXO板块全线大涨，药明系集体走高丨钛媒体焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2442929533","media":"钛媒体","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442929533?lang=zh_cn&edition=full","pubTime":"2024-06-12 17:38","pubTimestamp":1718185091,"startTime":"0","endTime":"0","summary":"药明康德率先回应，此前还获摩根大通增持6月12日，在药明康德举办的2023年年度股东大会上，其管理层针对上述消息作出回应。公司了解到，关于将《生物安全法案》加入2025国防授权法案的修正案未能获得众议院规则委员会的批准，因此《生物安全法案》目前不会进入众议院的2025国防授权法案的立法议程，其后续立法路径仍有待明确。在这一消息发酵之际，港A两市CXO板块大幅拉升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406121738189f347f2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406121738189f347f2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348735423.USD","LU1242518857.USD","LU0181495838.USD","LU0320764599.SGD","LU0856984785.SGD","LU0456827905.SGD","LU1794554557.SGD","LU0708995583.HKD","LU0043850808.USD","LU0307460666.USD","LU0039217434.USD","LU0516422440.USD","LU0417516902.SGD","LU0516423091.SGD","LU0327786744.USD","LU0823426308.USD","LU0819121731.USD","LU1688375341.USD","02268","BK1576","BK1610","LU2039709279.SGD","BK1521","JPM","02359","SG9999002562.SGD","IE00B0JY6N72.USD","02269","LU0417516738.SGD","SG9999002463.SGD","LU0140636845.USD","LU0051755006.USD","LU0588546209.SGD","BK1141","LU0326950275.SGD","LU0516422366.SGD","603259","LU0823426480.USD","LU0359202008.SGD","LU0359201612.USD","LU0979878070.USD","LU1880383366.USD","BK1589","SG9999014674.SGD","LU0052750758.USD","LU0516423174.USD","LU0348825331.USD","LU1720050803.USD","01548","LU0516422952.EUR","LU1242518931.SGD","LU0456846285.SGD","BK1583"],"gpt_icon":0},{"id":"2442758374","title":"CRO概念早盘普涨 药明合联及药明生物均涨逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2442758374","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442758374?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:48","pubTimestamp":1718160519,"startTime":"0","endTime":"0","summary":"CRO概念早盘普涨，药明合联（02268）上涨8.19%，报16.38港元；药明生物（02269）上涨7.83%，报11.84港元；药明康德（02359）上涨5.43%，报34.95港元；君实生物（01877）上涨4.60%，报12.74港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-12/doc-inaymwmi7605697.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-12/doc-inaymwmi7605697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["LU0348735423.USD","LU1242518857.USD","LU0181495838.USD","LU0320764599.SGD","LU0856984785.SGD","LU0456827905.SGD","LU1794554557.SGD","LU0708995583.HKD","LU0043850808.USD","LU0307460666.USD","LU0039217434.USD","LU0516422440.USD","LU0417516902.SGD","LU0516423091.SGD","LU0327786744.USD","LU0823426308.USD","LU0819121731.USD","LU1688375341.USD","02268","BK1576","BK1610","LU2039709279.SGD","BK1521","LU0572944931.SGD","SG9999002562.SGD","IE00B0JY6N72.USD","02269","LU0417516738.SGD","LU0140636845.USD","LU0051755006.USD","LU0588546209.SGD","BK1141","LU0326950275.SGD","LU0516422366.SGD","LU0823426480.USD","LU0359202008.SGD","LU0359201612.USD","LU0979878070.USD","LU1880383366.USD","BK1589","SG9999014674.SGD","LU0052750758.USD","LU0516423174.USD","LU0348825331.USD","LU1720050803.USD","LU0516422952.EUR","LU1242518931.SGD","LU0456846285.SGD","SG9999002463.SGD"],"gpt_icon":0},{"id":"2442819372","title":"生物制药板块逆市走高 药明合联(02268)涨超7% 机构料行业整体表现将逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2442819372","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442819372?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:43","pubTimestamp":1718160229,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物制药板块逆市走高，药明系领涨，药明合联 涨6.87%，药明生物涨5.28%，药明康德涨4.07%。进入2024年，一季度医药行业全板块的营收同比略微下降了0.21%，这表明基数效应和合规要求提升的影响仍在持续。但研报预计，从第二季度开始，随着高基数因素的影响逐步减弱，以及企业对合规新常态的适应，整体增速将逐步企稳。这表明，尽管医药行业在短期内面临一些挑战，但随着时间的推移和行业适应性的提高，预计行业的整体表现将逐步改善。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1938479","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","IE00B0JY6N72.USD","LU0823426480.USD","LU0456846285.SGD","LU2242644610.SGD","LU0856984785.SGD","BK1574","02359","LU0181495838.USD","LU1720050803.USD","BK1576","LU0516422440.USD","LU0051755006.USD","BK1589","BK1161","LU1880383366.USD","LU0823426308.USD","BK1583","LU0326950275.SGD","LU0819121731.USD","LU2045819591.USD","02269","LU0348735423.USD","SG9999014674.SGD","01228","LU1242518931.SGD","SG9999002562.SGD","BK1521","LU0456827905.SGD","LU0417516738.SGD","LU0417516902.SGD","LU0516423174.USD","LU0516422952.EUR","BK1141","LU0516422366.SGD","LU0052750758.USD","LU1794554557.SGD","BK1515","02268","LU0516423091.SGD","01672","LU0140636845.USD","LU0359202008.SGD","LU0572944931.SGD","LU0708995583.HKD","LU0348825331.USD","LU0979878070.USD","LU0327786744.USD","LU1242518857.USD","LU2039709279.SGD"],"gpt_icon":0},{"id":"2442374603","title":"港股异动 | 药明合联(02268)涨超8%领涨CRO概念 下游需求端有待好转 板块整体估值处于低位","url":"https://stock-news.laohu8.com/highlight/detail?id=2442374603","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442374603?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:41","pubTimestamp":1718160067,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念早盘普涨，截至发稿，药明合联涨6.87%，报16.18港元；药明生物涨5.28%，报11.56港元；药明康德涨4.07%，报34.5港元；君实生物涨2.79%，报12.52港元。中信建投指出，目前医药领域一级投融资仍有待恢复，下游需求端有待好转。临床CRO领域匹配高端需求的公司有望获得更高份额。目前CXO板块整体估值处于低位，长期来看，我们仍旧看好CXO板块发展潜力及成长空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320764599.SGD","LU0348825331.USD","LU0572944931.SGD","BK1589","LU1880383366.USD","01877","LU0327786744.USD","LU0516423091.SGD","LU2242644610.SGD","SG9999002562.SGD","LU0516423174.USD","02268","LU0140636845.USD","LU0348735423.USD","BK1141","LU0417516738.SGD","LU1242518931.SGD","LU0516422440.USD","LU0456827905.SGD","02359","LU2125910500.SGD","YANG","LU0823426480.USD","LU1046422090.SGD","LU0456846285.SGD","BK1161","LU2039709279.SGD","BK1515","LU1720050803.USD","LU0181495838.USD","07226","LU0823426308.USD","LU0043850808.USD","BK1583","LU0359202008.SGD","LU1794554557.SGD","LU0819121731.USD","BK1610","LU1242518857.USD","BK1576","02269","IE00B0JY6N72.USD","LU1688375341.USD","LU0516422366.SGD","SG9999014674.SGD","LU0856984785.SGD","HSCEI","HSTECH","LU0417516902.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2442740653","title":"药明合联(02268)股价上升5.02%，现价港币$15.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2442740653","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442740653?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:34","pubTimestamp":1718159640,"startTime":"0","endTime":"0","summary":"[上升股]药明合联(02268) 股价在上午10:34比前收市价上升5.02%，现股价为港币$15.9。至目前为止，今日最高价为$15.9，而最低价为$15.2。总成交量为126.75万股，总成交金额为港币$1.961千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406121091/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2441553706","title":"南向资金6月6日净卖出药明合联3.55万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2441553706","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441553706?lang=zh_cn&edition=full","pubTime":"2024-06-07 09:31","pubTimestamp":1717723891,"startTime":"0","endTime":"0","summary":"6月6日，南向资金减持药明合联3.55万股连续3日减持。截止当日收盘，港股通共持有药明合联5578.50万股，占流通股4.65%。港股通减持金额前五个股分别为五矿资源、长城汽车、中国中药、李宁、理想汽车-W。药明合联近5个交易日上涨3.89%，港股通累计增持40.70万股；近20个交易日下跌15.85%，港股通累计增持1781.10万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406070942279596a17a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406070942279596a17a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2441172735","title":"【券商聚焦】交银国际料医药板块当前性价比高 但行业情绪未完全修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2441172735","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441172735?lang=zh_cn&edition=full","pubTime":"2024-06-06 08:46","pubTimestamp":1717634818,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际发布医药行业2024年下半年展望，认为医药板块当前性价比高，机构持仓已跌至低位，但行业情绪未完全修复。该行对于细分板块的偏好排序如下：处方药=创新药>高股息中药/流通>民营医院>CXO。该行建议关注分红比例较高的国企和央企。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/YzYxNDFlZjgyMzJhODg3YzE4YjBmZGM0MDEyNzIzMzU2NzAy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YzYxNDFlZjgyMzJhODg3YzE4YjBmZGM0MDEyNzIzMzU2NzAy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1938194","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06078","01548","LU0072913022.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU2328871848.SGD","01093","LU0140636845.USD","02096","BK1521","BK1574","159938","BK1583","02162","LU0326950275.SGD","LU0501845795.SGD","BK1191","09995","BK1209","LU0067412154.USD","BK1587","LU1993786604.SGD","SG9999004220.SGD","BK1147","BK1141","09939","LU1226287529.USD","BK1161","IE0008368742.USD","LU1969619763.USD","BK1576","IE00B543WZ88.USD","BK1515","02268","LU0880133367.SGD","03329","BK1589","SG9999014674.SGD","01177"],"gpt_icon":1},{"id":"2439932464","title":"生物医药板块走高 恒生医疗保健指数涨1.7% 乐普生物(02157)涨8.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439932464","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439932464?lang=zh_cn&edition=full","pubTime":"2024-05-31 13:48","pubTimestamp":1717134533,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走高，恒生医疗保健指数涨1.7%，成分股中，康方生物 涨36.09%领涨，另外，乐普生物涨8.28%，微创脑科学涨7.82%，科伦博泰生物涨7.77%，亚盛医药涨5.5%，药明合联涨5.23%。招银国际表示，维持中国医药行业24下半年需求复苏的共识。该行对于子板块的判断。海外临床CRO公司将继续维持较好的增长态势。海外临床前CRO以及生命科学上游公司仍需等待更加明确的订单复苏信号。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1937907","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348784397.USD","159506","LU0417516571.SGD","02157","IE00B5MMRT66.SGD","BK1574","LU0348783233.USD","BK1161","LU1720050803.USD","09926","IE00B543WZ88.USD","06990","06855","02268","02172","BK1100","SG9999014674.SGD","161726","BK1141","399441","LU1794554557.SGD"],"gpt_icon":0},{"id":"2439527930","title":"药明合联早盘涨逾6% 机构料公司受益ADC行业高景气发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2439527930","media":"新浪网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439527930?lang=zh_cn&edition=full","pubTime":"2024-05-31 11:58","pubTimestamp":1717127902,"startTime":"0","endTime":"0","summary":"药明合联早盘股价上涨5.76%，现报15.78港元，成交额2746.25万港元。民生证券指出，药明合联是全球领先的一站式ADC CRDMO龙头。受益于ADC行业的高景气发展，下游客户对XDCCRDMO外包需求保持强劲，公司业绩2023年实现了114%的收入增长和112%的经调整净利润增长，综合项目数量增加到143个，业务增长势头一直延续到2024年Q1。此外，公司新加坡生产基地开工建设，为服务海外客户商业化项目储备产能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240531121154957daf39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240531121154957daf39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2439620932","title":"港股异动 | 药明合联(02268)现涨超6% 公司受益ADC行业高景气发展 新加坡生产基地开工建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2439620932","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439620932?lang=zh_cn&edition=full","pubTime":"2024-05-31 11:48","pubTimestamp":1717127333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药明合联现涨超6%，截至发稿，涨5.63%，报15.76港元，成交额3747.4万港元。民生证券指出，药明合联是全球领先的一站式ADC CRDMO龙头。受益于ADC行业的高景气发展，下游客户对XDCCRDMO外包需求保持强劲，公司业绩2023年实现了114%的收入增长和112%的经调整净利润增长，综合项目数量增加到143个，业务增长势头一直延续到2024年Q1。此外，公司新加坡生产基地开工建设，为服务海外客户商业化项目储备产能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1128876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ES3.SI","STI.SI","07226","SG9999014674.SGD","LU0831103253.SGD","HSTECH","BK6523","SG9999004360.SGD","BK1141","BK4231","LU0898667661.SGD","ADC","LU0205439572.USD","BK6516","YANG","02268","SG9999001135.SGD","SG9999000343.SGD","FSTAS.SI","BK4080","HSCEI","S68.SI","BK6033","FSTM.SI","SG9999016042.SGD"],"gpt_icon":0},{"id":"2439709984","title":"药明合联(02268)上涨5.63%，报15.76元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2439709984","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439709984?lang=zh_cn&edition=full","pubTime":"2024-05-31 09:34","pubTimestamp":1717119251,"startTime":"0","endTime":"0","summary":"5月31日，药明合联(02268)盘中上涨5.63%，截至09:34，报15.76元/股，成交502.47万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/31093440843023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2438847076","title":"药明合联(02268)下跌5.03%，报14.36元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2438847076","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438847076?lang=zh_cn&edition=full","pubTime":"2024-05-27 10:18","pubTimestamp":1716776309,"startTime":"0","endTime":"0","summary":"5月27日，药明合联(02268)盘中下跌5.03%，截至10:18，报14.36元/股，成交1692.08万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/27101840782089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0},{"id":"2437402256","title":"药明合联5月21日获南向资金加仓211.45万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2437402256","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437402256?lang=zh_cn&edition=full","pubTime":"2024-05-22 09:31","pubTimestamp":1716341499,"startTime":"0","endTime":"0","summary":"5月21日, 南向资金增持药明合联211.45万股。截止当日收盘，港股通共持有药明合联5147.10万股，占流通股4.29%。药明合联近5个交易日下跌9.60%，港股通累计增持699.20万股；近20个交易日下跌9.91%，港股通累计增持1999.30万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052209422387856ebe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052209422387856ebe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2437461319","title":"药明合联(02268)下跌5.03%，报15.86元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2437461319","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437461319?lang=zh_cn&edition=full","pubTime":"2024-05-21 14:30","pubTimestamp":1716273024,"startTime":"0","endTime":"0","summary":"5月21日，药明合联(02268)盘中下跌5.03%，截至14:30，报15.86元/股，成交9892.82万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/21143040717796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02268","SG9999014674.SGD","BK1141"],"gpt_icon":0},{"id":"2437653451","title":"药明合联(02268)出现大手卖出180万股，成交价$16.17，涉资2.911千万","url":"https://stock-news.laohu8.com/highlight/detail?id=2437653451","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437653451?lang=zh_cn&edition=full","pubTime":"2024-05-21 10:39","pubTimestamp":1716259140,"startTime":"0","endTime":"0","summary":"[大手成交]药明合联(02268)在上午10:39出现大手卖出，成交量为180万，成交价为港币$16.17，涉资2.911千万。至目前为止，股价跌0.359%，今日最高价为$16.86，而最低价为$16.17，总成交量为312.081万股，总成交金额港币$5.111千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2405212764/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268","SG9999014674.SGD","BK1141"],"gpt_icon":0},{"id":"2435445645","title":"药明合联(02268)上涨5.06%，报17.86元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435445645","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435445645?lang=zh_cn&edition=full","pubTime":"2024-05-16 13:14","pubTimestamp":1715836476,"startTime":"0","endTime":"0","summary":"5月16日，药明合联(02268)盘中上涨5.06%，截至13:14，报17.86元/股，成交7823.2万元。药明合联生物技术有限公司是一家专注于提供包括抗体药物偶联物(ADC)在内的生物偶联药物研究、开发与制造服务的合同研究开发及制造组织(CRDMO)，具有全面的跨学科服务能力和专业知识。根据2022年弗若斯特沙利文的报告，该公司是全球第二大ADC等生物偶联药物CRDMO，市场份额从2020年的1.8%增长至2022年的9.8%，显示出迅速的业务拓展和市场占有率的提升。截至2023年年报，药明合联营业总收入21.24亿元、净利润2.84亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/16131440666480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"1134787772","title":"通过！药明系等来8年缓冲期，公司火速回应","url":"https://stock-news.laohu8.com/highlight/detail?id=1134787772","media":"券商中国","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/1134787772?lang=zh_cn&edition=full","pubTime":"2024-05-16 10:30","pubTimestamp":1715826620,"startTime":"0","endTime":"0","summary":"此次通过的《法案》为5月10日公布的最新版本，内容对中国公司相比之前的版本更为缓和。在此前的华大系、药明康德及子公司基础上，新增药明生物。药明康德回复投资者表示，从2024年一季度情况来看，公司总体表现稳定。3月6日，美国参议院国土安全与政府事务委员会听证会上，参议院版的《生物安全法案》以高票通过了针对药明康德的条款后，市场担忧情绪进一步加剧。","market":"sh","thumbnail":"https://static.tigerbbs.com/24f0bdaa9acddf01d7e7aeec2b60a55e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/24f0bdaa9acddf01d7e7aeec2b60a55e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02269","603259","02268"],"gpt_icon":1},{"id":"2435743615","title":"南向资金5月14日净买入药明合联15.38万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2435743615","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435743615?lang=zh_cn&edition=full","pubTime":"2024-05-16 09:31","pubTimestamp":1715823098,"startTime":"0","endTime":"0","summary":"5月14日, 南向资金增持药明合联15.38万股，连续5日增持。截止当日收盘，港股通共持有药明合联4463.28万股，占流通股3.71%。港股通增持金额前五个股分别为中国银行、中国移动、中国石油股份、中国石油化工股份、腾讯控股。药明合联近5个交易日下跌13.53%，港股通累计增持987.78万股；近20个交易日下跌7.31%，港股通累计增持1567.18万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516094719876e5c09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516094719876e5c09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2435561270","title":"药明合联05月14日获主力加仓2347万元 环比增加738.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435561270","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435561270?lang=zh_cn&edition=full","pubTime":"2024-05-14 16:15","pubTimestamp":1715674551,"startTime":"0","endTime":"0","summary":"05月14日, 药明合联股价跌1.73%，报收17.00元，成交金额2.61亿元，换手率1.24%，振幅9.13%，量比1.97。药明合联今日主力资金净流入2347万元，上一交易日主力净流入280万元，今日环比增加738.21%。该股近5个交易日下跌13.63%，主力资金累计净流入5863万元；近20日主力资金累计净流入8820万元，其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141616148b068bc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405141616148b068bc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999014674.SGD","BK1141","02268"],"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":0.0995},{"period":"1month","weight":-0.0376},{"period":"3month","weight":0.0474},{"period":"6month","weight":-0.4601},{"period":"1year","weight":-0.2058},{"period":"ytd","weight":-0.4888}],"compareEarnings":[{"period":"1week","weight":-0.0231},{"period":"1month","weight":-0.0593},{"period":"3month","weight":0.073},{"period":"6month","weight":0.0685},{"period":"1year","weight":-0.0952},{"period":"ytd","weight":0.0525}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"WuXi XDC Cayman Inc是一家主要从事提供抗体偶联药物（ADC）及更广泛生物偶联药物的合同研究、开发和生产服务（CRDMO）的控股公司。该公司通过两个分部开展其业务。按有偿服务基准的研究服务分部透过有偿服务合约向客户提供研究服务。按全时当量基准提供的研究服务分部提供一个项目小组，该小组的员工在特定时间内专门负责客户的研究。基于生物药和小分子药物，该公司还提供跨领域的综合服务，涵盖生物偶联药物及连接子及有效载荷的发现、工艺开发及药品生产质量管理规范（GMP）生产。该公司在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"药明合联","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药明合联,02268,药明合联股票,药明合联股票老虎,药明合联股票老虎国际,药明合联行情,药明合联股票行情,药明合联股价,药明合联股市,药明合联股票价格,药明合联股票交易,药明合联股票购买,药明合联股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药明合联(02268)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药明合联(02268)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}